J Gastroenterol

Mesenchymal stem cell therapy for acute and chronic pancreatitis.

June 25, 2017 ibdwatch

Related Articles Mesenchymal stem cell therapy for acute and chronic pancreatitis. J Gastroenterol. 2017 Jun 23;: Authors: Kawakubo K, Ohnishi S, Kuwatani M, Sakamoto N Abstract Mesenchymal stem cells (MSCs) have attracted attention as a cell source for regenerative medicine. In particular, MSCs have an anti-inflammatory effect by secreting several kinds of bioactive molecules. MSC therapy is now being applied to various gastrointestinal diseases, such as graft-versus-host disease, inflammatory bowel disease, and liver cirrhosis. Therefore, MSC therapy has the potential to be a novel treatment for acute and chronic pancreatitis…

A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1 year after leukocytapheresis.

June 10, 2017 ibdwatch

Related Articles A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1 year after leukocytapheresis. J Gastroenterol. 2017 Jun 08;: Authors: Kobayashi T, Matsuoka K, Yokoyama Y, Nakamura T, Ino T, Numata T, Shibata H, Aoki H, Matsuno Y, Hibi T Abstract BACKGROUND: Extracorporeal leukocytapheresis (LCAP) is effective for inducing remission of ulcerative colitis (UC). This retrospective observational study aimed to evaluate the clinical outcome at 1 year and identify risk factors for relapse of UC after LCAP. METHODS: Patients with active UC…

TGF-β in inflammatory bowel disease: a key regulator of immune cells, epithelium, and the intestinal microbiota.

May 24, 2017 ibdwatch

Related Articles TGF-β in inflammatory bowel disease: a key regulator of immune cells, epithelium, and the intestinal microbiota. J Gastroenterol. 2017 May 22;: Authors: Ihara S, Hirata Y, Koike K Abstract Inflammatory bowel disease (IBD) is defined as chronic intestinal inflammation, and includes ulcerative colitis and Crohn’s disease. Multiple factors are involved in the pathogenesis of IBD, and the condition is characterized by aberrant mucosal immune reactions to intestinal microbes in genetically susceptible hosts. Transforming growth factor-β (TGF-β) is an immune-suppressive cytokine produced by many cell types and activated by…

Erratum to: Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis.

April 14, 2017 ibdwatch

Related Articles Erratum to: Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 2017 Apr 12;: Authors: Suzuki Y, Motoya S, Hanai H, Hibi T, Nakamura S, Lazar A, Robinson AM, Skup M, Mostafa NM, Huang B, Thakkar R, Watanabe M PMID: 28405767 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/28405767?dopt=Abstract

Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study).

March 23, 2017 ibdwatch

Related Articles Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study). J Gastroenterol. 2017 Mar 21;: Authors: Hibi T, Imai Y, Senoo A, Ohta K, Ukyo Y Abstract BACKGROUND: The global phase 3 studies of golimumab [PURSUIT-SC and PURSUIT-maintenance (M)], an anti-tumor necrosis factor-α (anti-TNFα) antibody, have demonstrated clinical efficacy and safety as induction and maintenance therapies in patients with moderate to severely active ulcerative colitis (UC). This study aimed to evaluate the…

Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis.

March 23, 2017 ibdwatch

Related Articles Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 2017 Mar 20;: Authors: Suzuki Y, Motoya S, Hanai H, Hibi T, Nakamura S, Lazar A, Robinson AM, Skup M, Mostafa NM, Huang B, Thakkar R, Watanabe M Abstract BACKGROUND: The 52-week safety and efficacy of adalimumab in Japanese patients with moderately to severely active ulcerative colitis were demonstrated in a placebo-controlled phase 2/3 trial. Data from patients who enrolled in the open-label extension study are presented. METHODS: Remission and response…

Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn’s disease.

March 10, 2017March 10, 2017 ibdwatch

Related Articles Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn’s disease. J Gastroenterol. 2017 Mar 08;: Authors: Qiu Y, Chen BL, Mao R, Zhang SH, He Y, Zeng ZR, Ben-Horin S, Chen MH Abstract BACKGROUND: To review the frequency with which anti-TNF-α loses its effect and dose “intensification” is required for Crohn’s disease (CD) treatment. METHODS: Electronic databases were searched for eligible studies. Raw data from studies meeting inclusion criteria were pooled for effect estimates. Subgroup analyses were performed for exploration of heterogeneity…

Increased expression of IL12B mRNA transcribed from the risk haplotype for Crohn’s disease is a risk factor for disease relapse in Japanese patients.

February 24, 2017February 24, 2017 ibdwatch

Related Articles Increased expression of IL12B mRNA transcribed from the risk haplotype for Crohn’s disease is a risk factor for disease relapse in Japanese patients. J Gastroenterol. 2017 Feb 22;: Authors: Kakuta Y, Kimura T, Negoro K, Kuroha M, Shiga H, Endo K, Kinouchi Y, Shimosegawa T Abstract BACKGROUND: IL12B is a promising candidate for a susceptibility gene in Crohn’s disease (CD). The aim of this study was to perform a candidate gene analysis of IL12B in Japanese CD patients, investigate whether the genotype is associated with disease phenotypes, and…

What score should be used for evaluation of Crohn’s disease severity using magnetic resonance imaging?

December 31, 2016December 31, 2016 ibdwatch

What score should be used for evaluation of Crohn’s disease severity using magnetic resonance imaging? J Gastroenterol. 2016 Dec 29;: Authors: Buisson A, Hordonneau C, Goutte M, Bommelaer G PMID: 28035486 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/28035486?dopt=Abstract

The 2016 diagnostic criteria for primary sclerosing cholangitis.

December 7, 2016December 7, 2016 ibdwatch

Related Articles The 2016 diagnostic criteria for primary sclerosing cholangitis. J Gastroenterol. 2016 Dec 05; Authors: Nakazawa T, Notohara K, Tazuma S, Tanaka A, Isayama H, Tsuyuguchi T, Mori T, Takikawa H Abstract BACKGROUND: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown cause that is characterized pathologically by an inflammatory and fibrotic process centered on the epithelium, leading to diffuse biliary stenosis and increased wall thickness throughout the intra- and extra-hepatic biliary trees. A nationwide survey in Japan revealed several differences in the clinical aspects of…